GlassScriptPhysician profile
Kenneth A Perez
NPI 1497410914
$846.79
in general payments reported to CMS, 2019-2025
11 companies · $88.27 in 2025
The $88.27 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.07 · 2023: $257 · 2024: $461 · 2025: $88.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $259.31 | 2023-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $141.40 | 2023-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $129.76 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $91.78 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $72.97 | 2024 | Impella |
| Pfizer INC. | $49.97 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.13 | 2023-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2024 | |
| Impulse Dynamics (USA) INC. | $18.42 | 2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $14.44 | 2024 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.